Histogenics gambles on an FDA clearance with a missed end point

STRONG DATA FROM DISAPPOINTING NEOCART TRIAL (Orthopedics This Week)
So close, they were … Histogenics Corporation, that is. When it comes to biologics, you want high standards—and that is where the Waltham, Massachusetts company started.
Recently, they announced that their Phase 3 clinical trial of NeoCart—a restorative cell therapy—did not meet the primary endpoint of a statistically significant improvement in pain and function in a study one year after treatment as compared to microfracture.
But the silver lining is in the details, says the company.
President and CEO Adam Gridley told OTW...